Company CVAbout Syngene International Ltd 
Syngene International Ltd
Large Cap
Pharmaceuticals & Drugs
Syngene International Limited is an integrated research, development and manufacturing services organization serving global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Headquartered in India, the operations are driven by its highly qualified teams comprising ~6000 scientists and its state-of-the-art facilities, spread over 2.2 million sq. ft., across 3 locations in India: Bangalore, Hyderabad and Mangalore.
Company Coordinates
Company Details
Biocon SEZ Biocon Park, Plot No 2 & 3 Bommasandra Inds Bengaluru Karnataka : 560099
Registrar Details
Karvy Computershare Pvt Ltd., Karvy Selenium, Tower-B Plot No 31 & 32, Survey No 116/22, 115/24, 115/25, Financial District, Nanakramguda, Serilingampally, Mandal Ranga Reddy Dist, Hyderabad
Capital StructureCapital Structure
Present Equity Capital
INR 402.54 Cr
Number of Shares
40.25 Cr
Face Value
INR 10.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
24-Apr-2024
40.25
402.54
521981
10
Issued under ESOP Scheme
26-Apr-2023
40.2
402.01
580500
10
Issued under ESOP Scheme
27-Apr-2022
40.14
401.43
638000
10
Issued under ESOP Scheme
27-Apr-2021
40.08
400.80
796500
10
Issued under ESOP Scheme
11-Jun-2019
4
400.00
200000000
10
Bonus
11-Aug-2015
2
200.00
22000000
10
Public Issues
11-Aug-2015
2
200.00
22000000
10
Public Issues
10-Aug-2015
17.8
178.00
-22000000
10
Offer For Sale
10-Aug-2015
17.8
178.00
-22000000
10
Offer For Sale
27-Mar-2015
2
200.00
171931136
10
Bonus
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 27 Schemes (13.58%)
FIIs
Held by 272 FIIs (20.72%)
Promoter with highest holding
Biocon Limited (52.46%)
Highest Public shareholder
Icici Prudential Mutual Fund - Icici Prudential Ni (4.41%)
Individual Investors Holdings
5.45%
Board of Directors
Management
Designation
Remuneration
Kiran Mazumdar Shaw
Chairperson
82.3 lacs
Catherine Patricia Rosenberg
Director
72.5 lacs
Paul Frederick Blackburn
Independent Director
79.1 lacs
Vijay Kuchroo
Independent Director
72.5 lacs
Jonathan Hunt
Managing Director & CEO
8.47 cr
Vinita Bali
Lead Independent Director
75.8 lacs
Priyadarshnini Mahapatra
Company Sec. & Compli. Officer
0
Sharmila Karve
Independent Director
75.8 lacs
Carl Decicco
Director
53.0 lacs
Kush Parmar
Independent Director
56.1 lacs
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Contract Research and Manufacturing Services Income
1,715.60
93.97%
Export Incentives
54.80
3.00%
Other Operating Income
52.40
2.87%
Contract Research and Manufacturing Services Income
Contract Research and Manufacturing Services Income
Export Incentives
Export Incentives
Other Operating Income
Other Operating Income
Stock DNARevenue and Profits:
Net Sales:
944 Cr
(Quarterly Results - Dec 2024)
Net Profit:
131 Cr
Pharmaceuticals & Drugs
INR 28,325 Cr (Large Cap)
58.00
33
0.17%
-0.09
10.49%
6.32
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
